No Record Found
CALLS | PUTS | |||||||||
Total OI | Chg in Ol | Chg % Ol | LTP | Chg % | Strike Price | Chg % | LTP | Chg % OI | Chg in Ol | Total OI |
No Record Found
sector: Pharmaceuticals
as on 8/21/2023 1:45:11 PM
₹ 2.9 0.05 1.75No Record Found
No Record Found
Resolution Type | Desc. of Resolution | Lias Recommendation |
---|
Invest wise with Expert advice
Get better recommendations Make better investments.
Get better recommendations Make better investments.
By continuing, I accept the Terms & Conditions and agree to receive communication on Whatsapp
Demat Account
Trading Account
PROMOTER - TOTAL73.29%
Indian: 73.29%
Foreign: 0%
NON-PROMOTER - TOTAL 26.71%
Institutions: 0.01%
Non-Institutions: 26.71%
CUSTODIES - 0.00%
Custodies: 0.00%
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 12.17 | 31.88 | 214.80 | 229.75 |
yoy growth (%) | (61.83) | (85.16) | (6.51) | (11.73) |
Raw materials | (5.66) | (6.32) | (156.42) | (153.96) |
As % of sales | 46.55 | 19.83 | 72.82 | 67.01 |
Employee costs | (14.51) | (19.21) | (21.93) | (20.82) |
As % of sales | 119.27 | 60.25 | 10.21 | 9.06 |
Other costs | (3.77) | (21.03) | (57.50) | (74.39) |
As % of sales | 30.94 | 65.99 | 26.77 | 32.38 |
Operating profit | (11.77) | (14.69) | (21.06) | (19.42) |
OPM | (96.75) | (46.07) | (9.80) | (8.45) |
Depreciation | (17.33) | (17.35) | (24.24) | (24.89) |
Interest expense | (125.44) | (109.96) | (97.54) | (85.77) |
Other income | 0.06 | 0.25 | 1.59 | 2.79 |
Profit before tax | (154.47) | (141.74) | (141.25) | (127.29) |
Taxes | 32.76 | 27.66 | 22.31 | 9.56 |
Tax rate | (21.21) | (19.52) | (15.79) | (7.51) |
Minorities and other | -- | -- | -- | -- |
Adj. profit | (121.71) | (114.07) | (118.94) | (117.73) |
Exceptional items | -- | -- | -- | (0.10) |
Net profit | (121.71) | (114.07) | (118.94) | (117.83) |
yoy growth (%) | 6.70 | (4.09) | 0.94 | 1.10 |
NPM | (1,000.31) | (357.88) | (55.37) | (51.28) |
Y/e 31 Mar ( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Equity capital | 64.37 | 64.37 | 64.37 | 72.27 |
Preference capital | 76.71 | 76.71 | 76.71 | 125.21 |
Reserves | (747.24) | (625.67) | (511.29) | (208.70) |
Net worth | (606.16) | (484.59) | (370.21) | (11.22) |
Minority interest | 0.12 | 0.12 | 0.12 | 0.28 |
Debt | 558.87 | 558.87 | 561.55 | 641.94 |
Deferred tax liabilities (net) | -- | -- | -- | -- |
Total liabilities | (47.17) | 74.40 | 191.46 | 631 |
Fixed assets | 321.81 | 339.14 | 356.49 | 715.80 |
Intangible assets | -- | -- | -- | -- |
Investments | 2.40 | 2.40 | 2.40 | -- |
Deferred tax asset (net) | 165.83 | 133.12 | 105.35 | 63.91 |
Net working capital | (537.27) | (400.38) | (273.23) | (152.27) |
Inventories | 1.59 | 1.26 | 3.97 | 27.01 |
Inventory Days | 47.70 | 14.43 | -- | 45.90 |
Sundry debtors | -- | -- | -- | 3.66 |
Debtor days | -- | -- | -- | 6.22 |
Other current assets | 76.51 | 75.82 | 71.91 | 76.48 |
Sundry creditors | (7.81) | (7.93) | (11.87) | (51.20) |
Creditor days | 234.28 | 90.81 | -- | 87.00 |
Other current liabilities | (607.56) | (469.53) | (337.24) | (208.22) |
Cash | 0.06 | 0.11 | 0.45 | 3.55 |
Total assets | (47.17) | 74.39 | 191.46 | 630.99 |
Y/e 31 Mar ( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | (154.47) | (141.74) | (141.25) | (127.29) |
Depreciation | (17.33) | (17.35) | (24.24) | (24.89) |
Tax paid | 32.76 | 27.66 | 22.31 | 9.56 |
Working capital 27,893 | (695.54) | (516.99) | (285.30) | (172.78) |
Other operating items | -- | -- | -- | -- |
Operating cashflow | (834.58) | (648.41) | (428.49) | (315.39) |
Capital expenditure | 330.64 | 222.27 | 219.41 | 244.63 |
Free cash flow | (503.94) | (426.14) | (209.08) | (70.77) |
Equity raised | (216.66) | (97.12) | 267.46 | 212.32 |
Investments | (1.63) | 2.37 | (0.03) | 0.49 |
Debt financing/disposal | 642.15 | 219.11 | 218.74 | 372.96 |
Dividends paid | -- | -- | -- | -- |
Net in cash | (80.08) | (301.78) | 277.10 | 515.00 |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -61.827 | -85.16 | -6.51 | -11.726 |
Op profit growth | -19.836 | -30.256 | 8.421 | -45.674 |
EBIT growth | -8.636 | -27.289 | 5.285 | -26.508 |
Net profit growth | 6.698 | -4.094 | 0.944 | 1.099 |
Profitability ratios (%) | ||||
OPM | -96.755 | -46.073 | -9.803 | -8.453 |
EBIT margin | -238.63 | -99.702 | -20.348 | -18.069 |
Net profit margin | -1,000.311 | -357.877 | -55.374 | -51.285 |
RoCE | -213.26 | -9.01 | -6.308 | -4.649 |
RoNW | 5.579 | 11.504 | 207.506 | -19.131 |
RoA | -223.573 | -8.086 | -4.292 | -3.299 |
Per share ratios (₹) | ||||
EPS | -40.82 | -38.26 | 0 | 0 |
Dividend per share | 0 | 0 | 0 | 0 |
Cash EPS | -46.632 | -44.076 | -48.023 | -47.865 |
Book value per share | -213.26 | -9.01 | -6.308 | -4.649 |
Valuation ratios | ||||
P/E | -0.078 | -0.065 | 0 | 0 |
P/CEPS | -0.068 | -0.057 | -0.333 | -0.57 |
P/B | -0.014 | -0.013 | -0.35 | -4.667 |
EV/EBIDTA | -48.532 | -39.228 | -35.25 | -51.123 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 0 |
Tax payout | -21.207 | -19.518 | -15.793 | -7.509 |
Liquidity ratios | ||||
Debtor days | 0 | 20.955 | 56.068 | 122.922 |
Inventory days | 42.747 | 161.861 | 61.225 | 80.481 |
Creditor days | -119.989 | -231.767 | -72.566 | -59.684 |
Leverage ratios | ||||
Interest coverage | 0.231 | 0.289 | 0.448 | 0.484 |
Net debt / equity | -0.922 | -1.153 | -56.898 | -44.076 |
Net debt / op. profit | -47.467 | -38.048 | -30.318 | -39.579 |
Cost breakup (₹) | ||||
Material costs | -46.546 | -19.831 | -72.822 | -67.012 |
Employee costs | -119.267 | -60.253 | -10.212 | -9.061 |
Other costs | -30.942 | -65.989 | -26.769 | -32.38 |
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd | 1,506.25 | 87.73 | 3,61,399.83 | 721.31 | 0.76 | 4,903.66 | 100.23 |
Cipla Ltd | 1,339.45 | 29.12 | 1,08,146.52 | 1,038.40 | 0.63 | 3,444.92 | 346.47 |
Divis Laboratories Ltd | 3,791.95 | 73.80 | 1,00,664.36 | 358.00 | 0.79 | 1,808.00 | 474.52 |
Zydus Lifesciences Ltd | 983.05 | 36.80 | 98,917.83 | 450.40 | 0.61 | 2,225.10 | 145.11 |
Dr Reddys Laboratories Ltd | 5,916.80 | 22.73 | 98,703.03 | 1,034.80 | 0.68 | 5,081.80 | 1,453.13 |
Parenteral Drugs (India) Limited was incorporated in 1983 as a private limited company. In 1989, the Company established their first unit to manufacture I V Fluids in Polypropylene containers with a capacity of 18 lakh bottles per annum. In March 1994, the company was converted into a public limited company. Parenteral Drugs (India) is an India-based pharmaceutical company. The Company manufactures, and markets pharmaceutical products in India, including solid and liquid orals, such as antibiotics and anti-bacterial, anti-ulcerant, analgesics/anti-inflammatory, multivitamins and minerals, anxiolyic , antiprotozoal, anticold, anthelmintic, anti-histaminic, muscle relaxant, cardiac, antidiabetic, cough syrup, appetite enhancer and injections. The Company produces various therapeutic segments of In-Vitro (I V) Fluids, such as electrolytes, antibacterial, energy replenisher, irrigation solution, osmotic diuretic, dialysis solution. They produce 400-milligram Ciprofloxacin infusion in 200 milliliter with 5% dextose. Apart from the single dose dispensers, the Company launched multi-dose eye/ ear drops in plastic containers. The dispensers are made using the form-fill-seal technology.In September 1994, the Company came out with a Public Issue at a premium of Rs 80, aggregating Rs 7.03 crore, to part-finance their Rs 8.97 Cr. expansion. During the year 1994-95, the Company set up a joint venture unit in Ukraine for manufacture of a wide range of pharmaceuticals. In addition, they... Read More
Reports by Parenteral Drugs (India) Ltd
Reports by Parenteral Drugs (India) Ltd
No Record Found
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Copyright © IIFL Securities Ltd. All rights Reserved.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Copyright © IIFL Securities Ltd. All rights Reserved.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.